摘要
肝细胞癌在我国的发病率和死亡率远高于其他国家或地区。门脉癌栓是晚期肝细胞癌最常见的并发症,会使病情急剧恶化,严重危害患者生命。对于可切除患者,仍然首选外科治疗,但对于更多的不可切除患者,一直没有有效的治疗手段。近年来随着放疗技术的进步,放疗在肝癌中的应用逐渐增多,地位也不断提升。在与索拉非尼、介入、射频等对比中,放疗均显示出明显的生存获益和技术优势。本文对放疗及其联合治疗在肝癌伴门脉癌栓中的临床进展做一综述。
The incidence and mortality of hepatocellular carcinoma(HCC) in our country is much higher than other countries or regions. Portal vein tumor thrombosis(PVTT) is the most common complication of advanced HCC, which causes a sharp deterioration and a serious damage to patients. For patients who are resectable, surgical treatment is still be preferred. But there has been no effective treatments.for unresectable patients. With the progress of radiation technology in recent years, radiotherapy(RT) has been applied to HCC more and more, the status is also rising. Compared with sorafenib, intervention and radiofrequency, RT had showed significant survival benefit and technology advantage. In this review, we tried to progress on RT and its combination therapy in HCC with PVTT.
出处
《肝癌电子杂志》
2016年第3期36-42,共7页
Electronic Journal of Liver Tumor
关键词
肝细胞癌
门脉癌栓
放疗
联合治疗
综述
Hepatocellular carcinoma
Portal vein tumor thrombosis
Radiotherapy
Combination therapy
Review
